Clinical study showing the potential of Histotype Px® Colorectal to predict adjuvant chemotherapy benefit in colon cancer patients to be presented at ASCO GI 2026
Clinical study showing the potential of Histotype Px® Colorectal to predict adjuvant chemotherapy benefit in colon cancer patients to be presented at ASCO GI 2026
OSLO – January 7, 2026 – DoMore Diagnostics, a leader in AI and deep-learning for precision medicine for cancer, is pleased to announce that a poster with clinical data on Histotype Px® Colorectal (Histotype Px) will be presented at the 2026 ASCO Gastrointestinal Cancers Symposium (ASCO GI 2026), taking place January 8–10, 2026 in San Francisco, California. The study was performed in collaboration with the Ohio State University Comprehensive Cancer Center (OSUCCC) and validates the potential of Histotype Px to predict adjuvant chemotherapy (ACT) benefit after surgery in patients with high-risk stage II and stage III colon cancer.
This retrospective analysis included 503 stage II/III colon cancer patients (51% receiving ACT) treated at OSUCCC between 2011 and 2024. Blinded to clinical outcomes, routine H&E-stained whole-slide images were analyzed by Histotype Px with Cancer-specific survival as the primary endpoint.
The digital biomarker was statistically significant in both univariable (p<0.0001) and multivariable analysis alongside clinicopathological markers (p=0.0010). Histotype Px separated patients into groups with distinct different outcomes: the low-risk group had excellent outcomes whether or not patients received ACT, and the intermediate-risk group also showed no apparent improvement with ACT. In contrast, the high-risk group had poor outcomes, and high-risk patients who received ACT had better cancer-specific survival than those who did not. In multivariable analyses, ACT benefit was observed only in the high-risk group (HR 0.17, 95% CI 0.06–0.47; p=0.0007) but neither in the intermediate-risk (p=0.84) nor low-risk (p=0.16) group.
The decision to offer ACT for patients with high-risk stage II and stage III colon cancer is challenging, as many patients do not benefit from this toxic and harmful therapy. The promising results of the present study further support the predictive utility of Histotype Px in identifying patients most likely to benefit from ACT, and those who may be spared treatment-related toxicity.
Principal Investigator Dr. Eric D. Miller, MD, PhD, at OSUCCC said: “In line with current US clinical guidelines, most stage II and stage III colon cancer patients receive adjuvant chemotherapy despite few patients benefitting. In our cohort, patients classified as Histotype Px low-risk had excellent cancer-specific outcomes with no meaningful difference whether they received ACT or not. This strongly suggests that this group can be considered for de-escalation of treatment. That is a very positive step forward, because it means we may be able personalize treatment decision and spare a substantial number of patients the toxicity of treatment without compromising survival”
Torbjørn Furuseth, MD, CEO and co-founder of DoMore Diagnostics, commented: “These results are groundbreaking and show the clinical utility of Histotype Px to guide personalized adjuvant chemotherapy in stage II/III colon cancer. We are highly encouraged by these results in U.S. patients as it constitutes important evidence to bring Histotype Px to routine clinical practice.”
This study was supported by an EIC Accelerator grant awarded to DoMore Diagnostics from the European Commission under Horizon Europe.
About DoMore Diagnostics
DoMore Diagnostics uses artificial intelligence to make personalized treatment decisions simple and accessible for all cancer patients. Its unique digital biomarkers predict patient outcomes from routine tumor tissue slides and can be seamlessly integrated into pathologists’ existing workflow. The lead product Histotype Px® Colorectal is a CE-IVDD marked outcome prediction marker for stage II and III colorectal adenocarcinoma that informs the decision of whether to provide adjuvant chemotherapy following surgical resection of the tumor.
About Colorectal Cancer and Histotype Px® Colorectal
Colorectal cancer is the third most common and second most deadly cancer but has seen little improvement in diagnostics and therapies over the last decades. Adjuvant chemotherapy (ACT) is routinely provided in high-risk stage II and stage III patients after primary surgery to prevent the disease from recurring. Due to lack of useful biomarkers overtreatment is prevalent in up to 90% of patients not benefitting from ACT and only suffering side effects.
Histotype Px® is an advanced deep learning algorithm that analyzes digital histology slides, separating patients into distinct Low, Intermediate and High-risk groups to guide ACT treatment decisions. Data previously published in The Lancet and The Lancet Oncology showed that the test can accurately predict survival outcomes in colorectal cancer patients. Histotype Px® Colorectal was developed to provide clinicians with valuable information to guide personalized treatment decisions and improve patient outcomes. Histotype Px® is for research use only (ROU) outside the EU.
For more information, please visit:
The Lancet publication.
The Lancet Oncology publication.
Contact:
Torbjørn Furuseth, MD
DoMore Diagnostics